A study of unprotected left main intervention in the ACS population 2013-2018

Sarma VRSS, Gopalakrishna K, Purnachandra Rao K, Somasekahr G, Chowdary PSS, Raghuram P, Boochibabu M, Sasidhar Y et al.

Indian heart journal, 2021

Abstract

OBJECTIVES: Our objectives were to evaluate the outcomes of left main percutaneous coronary interventions in Acute Coronary Syndrome population.

METHODS: This is a retrospective& observational study. Primary endpoint is a composite of death, stent thrombosis/MI, target lesion revascularization. Secondary endpoints include individual components of the primary events analyzed separately.

RESULTS: Seventy five patients, two year follow - up data was analyzed. The primary event analysis showed that the Elective Double Stent (EDS) group had a higher primary events (36% vs. 14%, p value - 0.008, Hazard ratio - 0.76 (0.51-1.15, 95% CI), in secondary event analysis stent thrombosis (ST)/Myocardial infarction (MI) rates were higher in EDS group (8% Vs 36%, p Value - 0.008, Hazard ratio- 0.63(0.35-1.14, 95%CI), there is no difference in target lesion revascularization (TLR)and death rates in both the groups.

CONCLUSIONS: The provisional strategy is better than EDS in treatment of left main bifurcation lesions in the ACS population.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices Molecular & Cellular Proteomics, 2011
The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities Proceedings of the National Academy of Sciences, 2000
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling British Journal of Pharmacology, 2007
In silico prediction of splice-altering single nucleotide variants in the human genome Nucleic Acids Research, 2014
In silico clinical trials: how computer simulation will transform the biomedical industry International Journal of Clinical Trials, 2016
In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design Nature Communications, 2018

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free